MetLife Investment Management’s Phathom Pharmaceuticals PHAT Stock Holding History

MetLife Investment Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$305K	Buy	28,107 +2,262	+9%	+$25.8K	﹤0.01%	2199
2026 Q1	$287K	Hold	25,845	–	–	﹤0.01%	2027
2025 Q4	$429K	Hold	25,845	–	–	﹤0.01%	1870
2025 Q3	$304K	Hold	25,845	–	–	﹤0.01%	2078
2025 Q2	$248K	Buy	25,845 +1,479	+6%	+$8.18K	﹤0.01%	2075
2025 Q1	$153K	Hold	24,366	–	–	﹤0.01%	2330
2024 Q4	$198K	Buy	24,366 +5,337	+28%	+$66.1K	﹤0.01%	2312
2024 Q3	$344K	Buy	19,029 +740	+4%	+$10.3K	﹤0.01%	1982
2024 Q2	$188K	Buy	18,289 +1,818	+11%	+$18.7K	﹤0.01%	2282
2024 Q1	$175K	Hold	16,471	–	–	﹤0.01%	2266
2023 Q4	$150K	Hold	16,471	–	–	﹤0.01%	2393
2023 Q3	$171K	Buy	16,471 +4,169	+34%	+$57.2K	﹤0.01%	2296
2023 Q2	$176K	Hold	12,302	–	–	﹤0.01%	2356
2023 Q1	$87.8K	Hold	12,302	–	–	﹤0.01%	2601
2022 Q4	$138K	Hold	12,302	–	–	﹤0.01%	2452
2022 Q3	$136K	Hold	12,302	–	–	﹤0.01%	2520
2022 Q2	$104K	Hold	12,302	–	–	﹤0.01%	2699
2022 Q1	$167K	Buy	12,302 +4,540	+58%	+$73.3K	﹤0.01%	2462
2021 Q4	$153K	Hold	7,762	–	–	﹤0.01%	2219
2021 Q3	$249K	Hold	7,762	–	–	﹤0.01%	1947
2021 Q2	$263K	Buy	7,762 +2,674	+53%	+$95.8K	﹤0.01%	1981
2021 Q1	$191K	Hold	5,088	–	–	﹤0.01%	2077
2020 Q4	$169K	Hold	5,088	–	–	﹤0.01%	2070
2020 Q3	$187K	Hold	5,088	–	–	﹤0.01%	1903
2020 Q2	$167K	Hold	5,088	–	–	﹤0.01%	2003
2020 Q1	$131K	Buy	+5,088	New	+$170K	﹤0.01%	1931

Other funds holding PHAT

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

MetLife Investment Management's PHAT Position: Q2 2026 in Review

MetLife Investment Management increased its Phathom Pharmaceuticals (PHAT) stake by 8.8% in Q2 2026, buying an estimated $25.8K and bringing the position to 28,107 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #2199.

MetLife Investment Management first reported a position in PHAT in Q1 2020 and has held it in 26 quarters since. The position peaked at $429K in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

MetLife Investment Management held 28,107 shares of Phathom Pharmaceuticals worth $305K as of Q2 2026.
MetLife Investment Management bought 2,262 Phathom Pharmaceuticals shares in Q2 2026, an estimated $25.8K.
Phathom Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2199 holding.
MetLife Investment Management first reported a position in Phathom Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
MetLife Investment Management's Phathom Pharmaceuticals position peaked at $429K in Q4 2025.
161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.